Cognitive Impairment as a Sequela of COVID-19 : Pathophysiology and Prospects for Treatment
Cognitive impairment has been reported as a potential sequela of COVID-19. Risk factors associated with this impairment include advanced age, severe infection, and prolonged duration of anosmia (loss of smell). Furthermore, COVID-19 has been reported as a risk factor for Alzheimer disease, and even mild infections have been associated with visuospatial cognitive impairments. While multiple pathophysiological mechanisms have been implicated in COVID-19-related cognitive impairment, persistent infection by the SARS-CoV-2 virus is of particular interest due to its potential implications for treatment. Persistent infection could lead to cognitive impairments through mechanisms such as neurotoxicity mediated by spike proteins, neuroinflammation induced by cytokines, and neuronal cell fusion (syncytia). In terms of treatment, the effectiveness of vaccination has been demonstrated in meta-analyses, and drugs like metformin and antiviral agents hold promise.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Rinsho shinkeigaku = Clinical neurology - 63(2023), 11 vom: 23. Nov., Seite 725-731 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Shimohata, Takayoshi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alzheimer disease |
|---|
| Anmerkungen: |
Date Completed 28.11.2023 Date Revised 28.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.5692/clinicalneurol.cn-001902 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363723218 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363723218 | ||
| 003 | DE-627 | ||
| 005 | 20231226093945.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.5692/clinicalneurol.cn-001902 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1212.xml |
| 035 | |a (DE-627)NLM363723218 | ||
| 035 | |a (NLM)37880112 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Shimohata, Takayoshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cognitive Impairment as a Sequela of COVID-19 |b Pathophysiology and Prospects for Treatment |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.11.2023 | ||
| 500 | |a Date Revised 28.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Cognitive impairment has been reported as a potential sequela of COVID-19. Risk factors associated with this impairment include advanced age, severe infection, and prolonged duration of anosmia (loss of smell). Furthermore, COVID-19 has been reported as a risk factor for Alzheimer disease, and even mild infections have been associated with visuospatial cognitive impairments. While multiple pathophysiological mechanisms have been implicated in COVID-19-related cognitive impairment, persistent infection by the SARS-CoV-2 virus is of particular interest due to its potential implications for treatment. Persistent infection could lead to cognitive impairments through mechanisms such as neurotoxicity mediated by spike proteins, neuroinflammation induced by cytokines, and neuronal cell fusion (syncytia). In terms of treatment, the effectiveness of vaccination has been demonstrated in meta-analyses, and drugs like metformin and antiviral agents hold promise | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alzheimer disease | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a cognitive impairment | |
| 650 | 4 | |a persistent infection | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Rinsho shinkeigaku = Clinical neurology |d 1972 |g 63(2023), 11 vom: 23. Nov., Seite 725-731 |w (DE-627)NLM000226874 |x 1882-0654 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2023 |g number:11 |g day:23 |g month:11 |g pages:725-731 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5692/clinicalneurol.cn-001902 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2023 |e 11 |b 23 |c 11 |h 725-731 | ||